Hide metadata

dc.date.accessioned2023-12-12T17:30:36Z
dc.date.available2023-12-12T17:30:36Z
dc.date.created2023-09-11T19:38:31Z
dc.date.issued2023
dc.identifier.citationLynghaug, Trine Bakke, Håkon Kvåle Fuskevåg, Ole Martin Nielsen, Erik Waage Dietrichs, Erik Sveberg . How should tranexamic acid be administered in haemorrhagic shock? - continuous serum concentration measurements in a swine model. Shock. 2023
dc.identifier.urihttp://hdl.handle.net/10852/106294
dc.description.abstractABSTRACT Background : Tranexamic acid (TXA) reduces mortality in trauma patients. Intramuscular (IM) administration could be advantageous in low-resource and military settings. Achieving the same serum concentration as intravenous (IV) administration is important to achieve equal mortality reduction. Therefore, we aimed to investigate whether dividing an IM dose of TXA between two injection sites and whether an increase in dose would lead to serum concentrations comparable to those achieved by IV administration. Methods : Norwegian landrace pigs (n = 29) from a course in hemostatic emergency surgery were given TXA 1 h after start of surgery. Blood samples were drawn at 0, 5, 10, 15, 20, 25, 35, 45, 60, and 85 min. The samples were centrifuged and serum TXA concentrations quantified with liquid chromatography-tandem mass spectrometry. The use of two injection sites was compared with distributing the dose on one injection site, and a dose of 15 mg/kg was compared with a dose of 30 mg/kg. All IM groups were compared with IV administration. Results : The groups were in a similar degree of shock. Increasing the IM dose from the standard of 15 mg/kg to 30 mg/kg resulted in significantly higher serum concentrations of TXA, comparable to those achieved by IV administration. Distributing the IM dose on two injection sites did not affect drug uptake, as shown by equal serum concentrations. Conclusions : For IM administration of TXA, 30 mg/kg should be the standard dose. With a short delay, IM administration will provide equal serum concentrations as IV administration, above what is considered necessary to inhibit fibrinolysis.
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleHow should tranexamic acid be administered in haemorrhagic shock? - continuous serum concentration measurements in a swine model
dc.title.alternativeENEngelskEnglishHow should tranexamic acid be administered in haemorrhagic shock? - continuous serum concentration measurements in a swine model
dc.typeJournal article
dc.creator.authorLynghaug, Trine
dc.creator.authorBakke, Håkon Kvåle
dc.creator.authorFuskevåg, Ole Martin
dc.creator.authorNielsen, Erik Waage
dc.creator.authorDietrichs, Erik Sveberg
cristin.unitcode185,53,18,12
cristin.unitnameAvdeling for immunologi og transfusjonsmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2174137
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Shock&rft.volume=&rft.spage=&rft.date=2023
dc.identifier.jtitleShock
dc.identifier.volume60
dc.identifier.issue5
dc.identifier.startpage707
dc.identifier.endpage712
dc.identifier.doihttps://doi.org/10.1097/SHK.0000000000002222
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1073-2322
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International